This analysis of data from 2 clinical trials examined the effect of benzodiazepines on outcomes in older patients with generalized anxiety disorder or major depressive disorder, including the likelihood of dropout, adherence, and treatment response.
Excessive and inappropriate emotional expressions may be exhibited months after a patient's stroke. Traditional SSRIs may help for a while, but as brain stem lesions progress, drugs that target other receptors may be necessary to treat chronic PSEI.
Treatment guidelines describe short-term use of medication for pediatric psychiatric disorders, but data suggest that long-term treatment is the norm. This study examined medication use over 5 years in 108 children diagnosed with an anxiety disorder.
Anxiety complaints are common among older adults, especially those with chronic illnesses. This narrative review describes the characteristics of common anxiety disorders among older people and provides treatment guidelines.
When you treat youth with anxiety disorders, are your decisions evidence-based? This meta-analysis examined efficacy and tolerability of agents studied for pediatric anxiety in double-blind, placebo-controlled trials. Read the article to learn which medication class fared best.
Which medication do you choose first when treating anxiety in children? This study used a large commercial claims database to determine which antianxiety medications clinicians are selecting as first-line treatment in pediatric patients.
Consistent evidence has correlated postpartum psychosis with later conversion to bipolar disorder; could episodes of nonpsychotic affective disorders following childbirth also be markers of underlying bipolar disorder? Read this journal CME research article to learn more.
The worries that characterize generalized anxiety disorder are so pervasive and excessive that they distort cognition and create a considerable burden of illness. See what the authors of this study found while evaluating the efficacy, safety, and tolerability of vilazodone as an acute treatment for GAD.
Older individuals with chronic illness often suffer considerable anxiety thinking about their illness. Although chronic illness alone represents something patients often can do little to control, they can learn ways to manage how they respond to anxious feelings. Read this Psychotherapy Casebook article to find out more.
The antidepressant efficacy of ketamine is clear, but what about its use in other psychiatric disorders? Read about a case of sustained symptom relief following a single ketamine infusion in a patient with treatment-refractory panic disorder, agoraphobia, and generalized anxiety disorder.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”